HRT: Weighing Benefits and Risks Without the Headlines

In 2002, a large American trial was stopped early and the news went around the world: hormone replacement therapy raised the risk of breast cancer. Prescriptions collapsed within months across the UK, Europe and beyond. A generation of women either stopped HRT abruptly or never started it, and a generation of doctors grew wary of offering it. Two decades later, the experts who ran that very trial have spent years explaining that the headline was, at best, half the story.

The HRT conversation is still recovering from that whiplash — a near-perfect case study in how a single number, stripped of its context, can frighten millions away from a treatment that for many of them was reasonable. So it is worth doing slowly: what HRT is for, what the evidence shows, what that 2002 trial really found, and why modern guidance frames the decision as a personal one rather than a verdict.

What HRT is, and what it's genuinely good at

Hormone replacement therapy replaces the oestrogen the ovaries stop producing, usually combined with a progestogen in women who still have a womb — because oestrogen alone thickens the womb lining and raises endometrial cancer risk, while adding a progestogen protects against that. Women without a womb can take oestrogen on its own.

On its core job, the evidence is not seriously disputed. For moderate-to-severe vasomotor symptoms — the hot flushes and night sweats that wreck sleep and derail days — HRT is the most effective treatment available, and the improvement in quality of life for women with disruptive symptoms can be substantial. It also protects bone: oestrogen reduces the accelerated bone loss of the menopausal years and lowers fracture risk while taken. For women with premature ovarian insufficiency or early menopause, replacing hormones until the usual age of menopause is recommended specifically because of the longer-term consequences of an early oestrogen deficit.

None of this makes HRT compulsory, and none of it makes it risk-free. It makes it a genuinely effective treatment with a real benefit profile — which is the necessary other half of any honest risk conversation.

The WHI story, told fairly

The trial that changed everything was the Women's Health Initiative. It was large, randomised, and well-conducted, and it genuinely advanced what we know. The problem was never the study — it was how its results were generalised.

Two things about its design mattered enormously and were widely overlooked. First, the average participant was around 63 — well past the typical age of menopause, not the woman in her early fifties starting HRT for hot flushes. Second, the regimens studied were specific oral preparations at particular doses, not the full range of modern options.

The widely reported finding — a modest increase in breast cancer risk in the combined oestrogen-plus-progestogen arm — was real but small in absolute terms, and crucially did not appear in the oestrogen-only arm. The stroke and clot risks that emerged were also concentrated in older women starting treatment years after menopause. Subsequent re-analyses sharpened a now-central idea: the balance of benefit and risk depends heavily on a woman's age and how close she is to menopause. For most women starting around the time of menopause for symptom relief, the picture looks considerably more favourable than the 2002 headlines implied.

What was over-extrapolated, then, was the leap from "this specific regimen, in women in their sixties" to "all HRT, for all women, is dangerous." Guidance has since evolved to reflect the nuance the headlines flattened.

Putting the risks in numbers

Vague risk is frightening; specific risk is manageable. So, in the spirit of the rest of this site, the numbers — held as estimates, not promises.

For breast cancer, combined HRT is associated with a small increase in risk that relates to the duration of use and tends to reduce after stopping, and is best understood alongside other everyday influences such as alcohol intake and body weight — several of which carry comparable or larger effects. Oestrogen-only HRT carries little or no increase. To keep proportion: the additional breast cancer cases attributable to combined HRT over several years of use are measured in a handful per thousand women, not a transformation of baseline risk.

For venous thromboembolism — blood clots — the route of delivery matters a great deal. Oral oestrogen carries a small increased clot risk; oestrogen delivered through the skin, as a patch, gel or spray, is not associated with the same increase at standard doses, because it bypasses the first pass through the liver. This is one of the most practically important facts in the field and one of the least known, and transdermal oestrogen likewise does not carry the stroke signal seen with some oral preparations at standard doses.

This is why a competent HRT discussion is never simply "yes or no." It is a discussion about type, dose and route — oral versus transdermal, which progestogen, how much — each of which moves the risk-benefit balance.

Why the decision belongs to the individual

If the risks and benefits varied identically for everyone, you could write a single rule. They don't, which is why guidance pushes the decision into the consultation room.

A woman's age, how close she is to menopause, the severity of her symptoms, her personal and family history of breast cancer, her clotting and cardiovascular risk, whether she has a womb, and her own values all feed into the balance. The same prescription that is a clear net benefit for one woman may be a poor choice for another. There is no single answer that survives contact with real people — and anyone offering one, in either direction (HRT as cure-all, or HRT as uniformly dangerous), is selling a certainty the evidence does not support.

What current UK guidance offers instead is a framework: consider HRT for women with troublesome symptoms after a discussion of benefits and risks; individualise type and route; review periodically; and recognise that for many women starting around the time of menopause, the benefits for symptom relief outweigh the risks. That is a structure for a decision, not the decision itself.

Practical takeaways

• For moderate-to-severe hot flushes and night sweats, HRT is the most effective treatment available, with real quality-of-life and bone benefits.
• The 2002 WHI scare was based largely on older women on specific oral regimens; its results were over-generalised to all women and all forms of HRT.
• Breast cancer risk from combined HRT is small in absolute terms, relates to duration, and largely reduces after stopping; oestrogen-only HRT carries little or none.
• Route matters: oestrogen through the skin (patch, gel, spray) avoids the clot and stroke risks associated with some oral forms at standard doses.
• The right choice depends on personal history, symptoms and values — there is no universal verdict.

What this doesn't mean

It doesn't mean HRT is risk-free or right for everyone — it carries genuine, if generally small, risks, and some women have conditions that make it unsuitable. Equally, it doesn't mean HRT is dangerous and best avoided; that conclusion misreads the evidence as badly as the opposite one. The honest position sits in the uncomfortable middle, where most good medicine lives.

When to seek medical advice

If menopausal symptoms are affecting your life and you want to understand your options, this is a conversation worth having with a GP or menopause-experienced clinician who can weigh your individual history. Seek prompt advice for any new breast lump, unexpected vaginal bleeding, or symptoms of a blood clot — calf swelling and pain, or sudden breathlessness and chest pain, the latter needing emergency assessment.

A closing thought

The HRT story is really a story about risk literacy. A real but small increase in one risk, reported without its denominator or its caveats, reshaped the health of millions of women for two decades. The useful response is not to swing to the opposite headline — "HRT is back, and it's wonderful" — but to insist on the harder, duller thing: the actual numbers, the role of route and timing, and a decision made with someone who knows your full history.

Further reading and sources

• NICE NG23 — Menopause: diagnosis and management
• British Menopause Society — consensus statements on HRT, including risks and benefits and prescribing
• Women's Health Initiative — original findings and subsequent re-analyses by the trial investigators
• MHRA — guidance and safety information on hormone replacement therapy
• NHS — benefits and risks of HRT

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.